Canada · Delayed Price · Currency is CAD Knight Therapeutics Company Description
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally.
It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.
The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation.
In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections.
Further, the company finances other life science companies; and invests in life sciences venture capital funds.
Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
| Country | Canada |
| Founded | 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 830 |
| CEO | Samira Sakhia |
Contact Details
Address: 100 Boul. Alexis-Nihon Montreal, QC QC Canada | |
| Phone | 514-484-4483 |
Stock Details
| Ticker Symbol | GUD |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA4990531069 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Samira Sakhia BCom, CA, CPA, MBA | President, Chief Executive Officer and Director |
| Jonathan Ross Goodman B.A., L.L.B., M.B.A. | Executive Chairman |
| Arvind Utchanah | Chief Financial Officer |
| Leopoldo Bosano | Vice-President of Manufacturing and Operations |
| Susan Caroline Emblem | Global Vice President of Human Resources |
| Amal Khouri B.Sc., M.B.A. | Chief Business Officer |
| Christine Poulin | General Manager of Canada |
| Monica Percario | Global Vice President of Regulatory and Quality |
| Henrique Dias | Global Vice President of Marketing |
| Melanie Groleau | Global Vice President of Medical and Clinical |